Summary information on the funding and supply of inclisiran (Leqvio®)

Document first published:
Page updated:
Topic:
Publication type:

This document describes the funding and supply arrangements for inclisiran (Leqvio®) as an option in the lipid management pathway. It notes inclisiran is funded centrally by NHS England and that in July 2024 these arrangements will be assessed. The current arrangements have been extended to the end of December 2024 and the position outlined in the document remains as is. Therefore during this time, and until notified otherwise, there is no impact on new or current patient access to this treatment. We will shortly update on an extension of the current arrangements from January 2025.

Summary

Updated 29 June 2023.